| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530388100 | Monoclonal | 81 |
| 20100063260 | Whitefly Ecdysone Receptor Antibody - The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity. | 03-11-2010 |
| 20130041139 | ENHANCED PROTEIN PURIFICATION THROUGH A MODIFIED PROTEIN A ELUTION - The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH. | 02-14-2013 |
| 20090124791 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 05-14-2009 |
| 20130046080 | METHOD TO IMPROE THE SORBENT EFFICIENCY OF PROTEIN A CHROMATOGRAPHY USING SWITCHING COLUMN WITH CONTINUOUS FEEDING - The present invention relates to a method to improve the sorbent efficiency of protein A chromatography using switching column with continuous feeding. In the chromatography method of the present invention, the increased usage efficiency of the absorbent (resin), the decreased processing time, the decreased operation cycle of column compared to that of single batch-type column, and the reduced amount of used resin are achieved and thus, the target protein can be purified at a high efficiency and a low cost. | 02-21-2013 |
| 20090012271 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 01-08-2009 |
| 20110144311 | METHODS FOR PURIFYING ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY - This invention provides a method for purifying a monomeric monoclonal antibody which comprises contacting the sample, wherein the sample comprises the monomeric monoclonal antibody, host cell impurities, dimers, and higher order aggregates, with a Protein A affinity chromatography column; eluting the monomeric monoclonal antibody from the Protein A affinity chromatography column with an elution buffer; and collecting one or more fractions of the monomeric monoclonal antibody to form a Protein A product pool, wherein the product pool comprises less than 5% higher order aggregate, and has a pH from about 3.2 to about 4.5, thereby purifying the monomeric monoclonal antibody from the sample. This invention also provides a method for purifying a monomeric monoclonal antibody which comprises eluting with acetate or citrate, optionally in the presence of amino acids. This invention also provides a method for purifying a monomeric monoclonal antibody which comprises conducting the method within certain temperature ranges. | 06-16-2011 |
| 20110288277 | Media For Membrane Ion Exchange Chromatography Based On Polymeric Primary Amines, Sorption Device Containing That Media, And Chromatography Scheme And Purification Method Using The Same - Media and devices, such as anion exchangers including such media, wherein the media is a membrane having a surface coated with a polymer such as a polyallylamine. The resulting membrane offers stronger binding of protein impurities and superior removal of host cell proteins from biological samples than conventional ligands based on quaternary ammonium salts, including trimethylammonium ligands. Also described is a chromatography scheme and method for purifying monoclonal antibodies, wherein the anion exchange sorber is placed downstream of an affinity column (such as Protein A or Protein G affinity column) and optionally one or more polishing devices such as cationic exchange columns. Little or no dilution of the cation exchanger pool (or affinity column exchange pool where no cation exchanger is used) is necessary to lower the conductivity of the sample. The sorber functions well to strongly bind host cell proteins and other impurities in biological samples even at high conductivities and pH. | 11-24-2011 |
| 20100087631 | ANTI-MYOSTATIN ANTIBODIES - A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may he chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species. | 04-08-2010 |
| 20100099854 | NEUROVIRULENT STRAIN OF THE WEST NILE VIRUS AND USES THEREOF - Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof. | 04-22-2010 |
| 20080306247 | ANTIBODY-CONTAINING SOLUTION FORMULATIONS - An antibody-containing solution formulation comprising an organic acid and a surfactant as stabilizers; a method for suppressing the formation of visible insoluble matter and/or insoluble particles due to the presence of metal ions in an antibody-containing solution formulation, which comprises adding an organic acid to the solution; a method for suppressing the formation of visible insoluble matter and/or insoluble particles during shaking and freezing-thawing of an antibody-containing solution, which comprises adding a surfactant to the solution; and a method for stabilizing an antibody-containing solution, which comprises adding an organic acid and a surfactant. | 12-11-2008 |
| 20120077963 | METHOD FOR REMOVING VIRUSES FROM HIGH CONCENTRATION MONOCLONAL ANTIBODY SOLUTION - An object of the present invention is to provide a method for removing even small viruses from a high concentration monoclonal antibody solution using a membrane, and thus for recovering the antibody within a short time at high yield in the form of a filtrate. The present invention provides a method for producing a preparation containing a monoclonal antibody, which comprises a step of removing viruses by filtering viruses in a monoclonal antibody solution using a virus-removing membrane, wherein
| 03-29-2012 |
| 20100174051 | Asymmertric porous adsorptive bead - The present invention relates to an asymmetric chromatography media suitable for separations applications, particularly as packed bed, fluidized bed or magnetized bed chromatography media. In certain embodiments, the asymmetric chromatography media comprises asymmetric particles, preferably beads, having at least two distinct, controlled pore size distributions. Preferably one of the distinct pore size distributions is in an internal region of the particle, and the other is in an external region or coating on the particle. These distinct pore size distributions can be modified with uniform or alternatively unique functional groups or mixtures of functional groups. The present invention allows for the control over pore size distribution within an asymmetric porous particle by providing a distinct internal region, preferably in the form of a bead, and a distinct external region, preferably in the form of a coating on the bead. | 07-08-2010 |
| 20100145031 | METHODS FOR PRODUCING ANTIBODIES FROM PLASMA CELLS - The invention relates to methods of producing antibodies, including monoclonal antibodies, comprising culturing a limited number of plasma cells. It also relates to methods of identifying antibodies by performing assays on the antibodies produced by the cultured plasma cells to determine their function, binding specificity, epitope specificity, and/or their ability to neutralize a toxin or a pathogen. The invention also relates to antibodies and antibody fragments produced by the methods of the invention as well as methods of using the antibodies and antibody fragments. | 06-10-2010 |
| 20090076251 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
| 20110118445 | Inhibitor protein of the wnt signal pathway - The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein. | 05-19-2011 |
| 20100298547 | METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE AS ANTIBODY LIGANDS - The instant invention comprises a process for selecting and manufacturing antibodies useful for therapeutic, prophylactic, diagnostic or research purposes using epitope peptide mixtures synthesized by the solid phase synthesis, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting antibodies are related to but distinct from antibodies that bind to the known epitope. | 11-25-2010 |
| 20100190965 | METHOD FOR SEPARATION OF IMMUNOGLOBULIN MONOMERS - A method of accurately separating immunoglobulin monomers by subjecting an immunoglobulin solution containing at least immunoglobulin monomers and immunoglobulin aggregates to cross-flow filtration using an ultrafiltration membrane, an ultrafiltration membrane module, and a cross-flow filtration apparatus. The method can separate immunoglobulin monomers by subjecting an immunoglobulin solution containing at least immunoglobulin monomers and immunoglobulin aggregates and having an immunoglobulin concentration of 1 to 150 g/L to cross-flow filtration using an ultrafiltration membrane having a molecular weight cut-off of 100,000 or more and less than 500,000 so that immunoglobulin monomers passes through the ultrafiltration membrane with a permeability of 80% or more while achieving a fractionation performance in which the permeability ratio of immunoglobulin dimers to immunoglobulin monomers that pass through the ultrafiltration membrane is 0.20 or less. | 07-29-2010 |
| 20110245472 | METHOD FOR THE MASS PRODUCTION OF IMMUNOGLOBULIN CONSTANT REGION - Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an | 10-06-2011 |
| 20120202975 | ELUTION OF PROTEINS FROM HYDROXYAPATITE RESINS WITHOUT RESIN DETERIORATION - Proteins, including monoclonal antibodies, that have been retained on hydroxyapatite resins for purposes of protein separation, purification, or both, are eluted from the resins by a elution buffer that contains controlled amounts of calcium and phosphate ions. The buffer allows elution to be performed in repeated runs at an acidic pH without deterioration of the resin. | 08-09-2012 |
| 20120202976 | SEPARATION MATRICES - The present invention relates to separation matrices comprising base matrices with first ligands comprising hydrophobic functions covalently bound to said base matrices and with extenders covalently bound to said base matrices, said extenders comprising second ion exchange ligands. | 08-09-2012 |
| 20120149883 | Detection and quantification of modified proteins - The invention provides a method detecting and quantifying proteins by mass spectrophotometric analysis using peptide internal standards and provides a highly sensitive way of detecting protein modifications. In one aspect, the invention provides a method for determining a site of ubiquitination in a polypeptide and for evaluating ubiquitination targets in a population of polypeptides. In this way, a proteome ubiquitination map can be obtained which comprises information relating to the ubiquitination states of a plurality of cellular polypeptides. Maps can be obtained for a variety of different types of cells and cell states. For example, ubiquitination targets in normal and diseased cells can be evaluated. Preferably, the map is stored as data files in a database. Individual ubiquitinated polypeptides identified can be used to generate molecular probes diagnostic of a cell state and/or can serve as targets for agents that modulate one or more cellular processes. | 06-14-2012 |
| 20130012689 | Depth Filters For Disposable Biotechnological Processes - A process for the primary clarification of feeds, including chemically treated flocculated feeds, containing the target biomolecules of interest such as mAbs, mammalian cell cultures, or bacterial cell cultures, using a primary clarification depth filtration device without the use of a primary clarification centrifugation step or a primary clarification tangential flow microfiltration step. The primary clarification depth filtration device contains a porous depth filter having graded porous layers of varying pore ratings. The primary clarification depth filtration device filters fluid feeds, including chemically treated flocculated feeds containing flocculated cellular debris and colloidal particulates having a particle size distribution of approximately about 0.5 μm to 200 μm, at a flow rate of about 10 litres/m | 01-10-2013 |
| 20090259028 | PREVENTION OF LEACHING OF LIGANDS FROM AFFINITY-BASED PURIFICATION SYSTEMS - In an affinity-type purification, ligands dissociated from the stationary phase that would otherwise leach into the species being purified are captured by a second ligand that is also incorporated into the stationary phase, the second ligand exhibiting an affinity-type interaction with the dissociated first ligand with sufficient specificity to avoid the undesired retention by the second ligand of species from the liquid sample or source liquid other than the species sought to be purified in the affinity column. | 10-15-2009 |
| 20120010390 | SEPARATION METHOD USING SINGLE POLYMER PHASE SYSTEMS - The present invention relates to a process of enriching one target compound from a liquid, which process comprises at least one step of isolation performed by differentially partitioning between two aqueous phases. In the present invention the phases are formed by adding a thermally responsive, self-associating (i.e. clouding) hydrophilic polymer, and if needed some additional salts, to an aqueous biotechnical solution (such as a fermentation sample or bioseparation process stream) under thermal and other conditions where the solution separates into a one polymer, two-phase system with one phase enriched in the polymer. The target compound is to be found in the phase not enriched in the polymer, while a significant though varying percentage of contaminants may differentially partition to the phase interface or the polymer enriched phase. With minor or no modification the target containing phase solution can be further processed via standard unit operations such as precipitation, chromatography, and filtration to further purify target and remove any residual polymer. | 01-12-2012 |
| 20120022239 | PRECIPITATION OF BIOMOLECULES WITH NEGATIVELY CHARGED POLYMERS - The present invention relates to methods of isolating biomolecules. More particularly, the invention relates to methods for isolating antibodies (mAbs) and related proteins including antibody fragments (Fabs) under conditions where they are positive and relatively hydrophobic and will react with negatively charged polymer to form polymer-protein complexes which precipitate. The isolation can be accomplished using inexpensive and biocompatible negatively charged polymers such as polyacrylic acid or carboxymethyldextran polymers of various molecular weights as precipitant. It occurs at relatively high concentrations of polymer (e.g. 10%) and high salt concentration (>50 mM) and conductivity (e.g. > | 01-26-2012 |
| 20110065901 | Methods For Purifying A Target Protein From One or More Impurities In A Sample - The present invention relates, at least in part, to improved methods of protein purification. In particular, the present invention relates, at least in part, to methods for purifying an Fc region containing protein from a composition comprising the Fc region containing protein and one or more impurities, where the methods eliminate the need for a holding tank and/or a buffer exchange step. | 03-17-2011 |
| 20100204455 | Antibody Purification Process By Precipitation - The present invention relates to a method of purification of antibodies. An object of the present invention is to provide a method for the isolation of antibodies from a solution containing one or more antibodies, comprising the steps of precipitating the antibody and washing the solid precipitate with washing buffer. Preferably, the antibody is precipitated by using a PEG solution or sodium phosphate. | 08-12-2010 |
| 20100298548 | METHOD FOR PRODUCTION OF SEPARATION MEDIA - The present invention relates to a method for production of separation media using a so called Spinning Disc technology wherein the porosities of the beads are optimized in such a way that a desired biomolecule may be separated from a complex sample. The method comprises the following steps: a) feeding a 4-8% polysaccharide solution, which has a viscosity within 350-450 mPas, at 65-75° C. to one or more spinning discs at 3001-3010 rpm to form polysaccharide beads; b) capturing said formed polysaccharide beads in a capturing bath; wherein the porosity of the polysaccharide beads is controlled by varying the temperature of the capturing between 15 and 27° C., preferably between 17.5 and 24.6° C. The method yields porosities that prevent molecules larger than 150 000 g/mol to diffuse into the beads. The invention also relates to separation media produced by the method and use thereof for purification of biomolecules, in particular monoclonal antibodies. | 11-25-2010 |
| 20090018316 | Interleukin-15 receptors - There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures. | 01-15-2009 |
| 20120264920 | PROCESSES FOR PURIFICATION OF PROTEINS - The invention is directed to a method for purifying a protein. The method involves providing a sample containing the protein, processing the sample through a capture chromatography resin, inactivating viruses in the sample, and processing through at least one depth filter and ion-exchange membrane. | 10-18-2012 |
| 20100249383 | Novel Ligand Involved In The Transmigration Of Leukocytes Across the Endothelium and Uses Therefor - The present invention provides methods and compositions involved in the inflammatory response, as well as various pathological processes. In particular, the present invention provides novel antibodies directed against novel glycans that are enriched on endothelial cell surfaces. In addition, the present invention provides methods and compositions involved in a previously unrecognized pathway of the inflammatory response and various pathological processes. In addition the present invention provides methods and compositions suitable to mediate the inflammatory response in various settings, as well as methods and compositions for the identification of other inflammatory response mediators. | 09-30-2010 |
| 20100234577 | METHODS FOR PURIFYING ANTIBODIES USING CERAMIC HYDROXYAPATITE - This invention relates to the purification of monoclonal antibodies from mammalian cell culture fluid utilizing sequential, orthogonal chromatography and filtration techniques resulting in material of high purity and quality that is suitable for human administration. The method involves capturing an IgG product using immobilized protein A affinity chromatography, followed by at least one ion exchange technique prior to adsorbing the IgG to hydroxyapatite and selectively eluting the product in a single isocratic step to achieve purification from impurities and simultaneously reducing multiple types of impurities including but not limited to IgG aggregates, residual protein A, non-IgG proteins, host cell proteins, viral particles, and DNA | 09-16-2010 |
| 20100174052 | SEPARATION METHOD USING POLYMER MULTI PHASE SYSTEMS - The present invention relates to a process of isolating one or more target compounds, wherein the clarification of feed is performed using partitioning in a multiphase system comprising a first polymer, which is a synthetic poly(acid), a second synthetic polymer, which is a poly(ether), and at least one salt, which clarification is followed by at least one step of affinity chromatography. The molecular weight of the poly(acid) may be in the range of 1000-100,000 Da. The target compound is preferably a biomolecule, such as a monoclonal antibody. | 07-08-2010 |
| 20130023653 | Tissue Specific Expression Of Antibodies In Chickens - Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of trangene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems. | 01-24-2013 |
| 530388150 | Human | 8 |
| 20130046081 | FULLY HUMAN MONOCLONAL ANTIBODY TO VEGF, PREPARATION METHOD AND USE THEREOF - The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines. | 02-21-2013 |
| 20130072664 | HUMAN MONOCLONAL ANTIBODY HAVING FAT-REDUCING EFFECT - Purified polypeptide is proposed, the amino acid sequence of which is essentially identical to the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:3, the polypeptide binding low density lipoproteins (LDL) and/or oxidized LDL (oxLDL), in particular LDL cholesterol and/or oxidized LDL cholesterol (oxLDL cholesterol). | 03-21-2013 |
| 20120108796 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 05-03-2012 |
| 20100168400 | Superagonistic Anti-CD28 Antibodies - The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising
| 07-01-2010 |
| 20100056764 | Antibodies against human NKG2D and uses thereof - The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies. | 03-04-2010 |
| 20110118446 | METHODS AND COMPOSITIONS FOR ANTIBODY PRODUCTION - Methods and compositions for antibody production are described herein to produce human antibodies in immunodeficient mice. Particularly mice are implanted with human fetal thymus cells or human thymus and human liver tissue and human hematopoietic cells followed by immunization with an antigen. Immunization involves exposure to any of a variety of antigens including tumor antigens, microbial antigens, viral antigens and/or cytokines and growth factor. | 05-19-2011 |
| 20120046452 | ANTIBODY-MEDIATED REJECTION INHIBITOR - A purpose of the present disclosure to achieve transplantation from ABO-incompatible donors and inhibition of autoimmune disease, for example, without significantly impairing defense mechanisms. | 02-23-2012 |
| 20100010202 | Human antibodies derived from immunized xenomice - Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof. | 01-14-2010 |
| 530388200 | Binds microorganism or normal or mutant component or product thereof (e.g., animal cell, cell-surface antigen, secretory product, etc.) | 31 |
| 20120108795 | Antibodies Binding Human Collagen II - The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing. | 05-03-2012 |
| 20110054149 | NOGO-A Neutralizing Immunoglobulins for the Treatment of Neurological Diseases - The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. | 03-03-2011 |
| 20110275789 | Methods and Kits for Detection of Thromboxane A2 Metabolites - Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody. | 11-10-2011 |
| 20080312420 | Monoclonal Antibodies for Detection of Urinary Trypsin Inhibitors - Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof. | 12-18-2008 |
| 530388210 | Binds nucleic acid or derivative or component thereof (e.g., DNA, RNA, DNA-RNA hybrid, nucleotide, nucleoside, carcinogen-DNA adduct, etc.) | 1 |
| 20120184719 | HYBRIDOMA PRODUCING ANTI-METHYLATED DNA ANTIBODY AND UTILIZATION OF SAME - The present invention relates to a hybridoma producing an anti-methylated DNA antibody, obtained by cell fusion of an antibody-producing cell obtained from an animal immunized with an antigen containing 5′-(5-methyl-2′-deoxycytidine-3′-phospho)-2′-deoxyguanosine 3′-phosphate with a myeloma cell. The present invention also relates to a monoclonal antibody produced by the hybridoma and a method for immunoprecipitation of a methylated DNA using the antibody. | 07-19-2012 |
| 530388220 | Binds receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.) | 5 |
| 20120108797 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determine regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 05-03-2012 |
| 20110009602 | HUMAN CD28 SPECIFIC MONOCLONAL ANTIBODIES FOR ANTIGEN-NONSPECIFIC ACTIVATION OF T-LYMPHOCYTES - The invention teaches human-compatible monoclonal antibodies which are specific against human CD28 and human T-lymphocytes of several to all subgroups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically. | 01-13-2011 |
| 20110178279 | DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES - In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof. | 07-21-2011 |
| 20120178912 | RECEPTOR ACTIVATOR OF NF-kappaB - Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof. | 07-12-2012 |
| 20120253019 | NOVEL MONOCLONAL THYROID STIMULATING OR BLOCKING ANTIBODIES, PEPTIDE SEQUENCES CORRESPONDING TO THEIR VARIABLE REGIONS, AND THEIR USES IN DIAGNOSTIC, PREVENTIVE AND THERAPEUTIC MEDICINE - Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab′) | 10-04-2012 |
| 530388230 | Binds lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interleukin, interferon, erythropoietin, etc.) | 3 |
| 20110130548 | ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES - Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells T | 06-02-2011 |
| 20090082550 | ANTIBODY COMPOSITIONS AND METHODS - Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses. | 03-26-2009 |
| 20120157667 | Methods Of Producing Humanized Non-Human Mammals - Provided herein are methods of reconstituting functional human blood cell lineages in a non-human mammal comprising introducing human hematopoietic stem cells (HSCs) and nucleic acid encoding one or more human cytokines into an immunodeficient non-human mammal. The non-human mammal is maintained under conditions in which the nucleic acid is expressed and the human HSCs differentiate into functional human blood cell lineages in the non-human mammal, thereby reconstituting functional human blood cell lineages in the non-human mammal. Also provided are methods of producing human antibodies directed against an immunogen in a non-human mammal, hybridomas that secrete the monoclonal antibodies as well as antibodies (e.g., polyclonal antibodies; monoclonal antibodies) produced by the B cells and non-human mammals produced by the methods. | 06-21-2012 |
| 530388240 | Binds hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, intragonadal regulatory protein, Mullerian inhibiting substance, inhibin, epidermal growth factor, nerve growth factor, dopamine, norepinephrine, etc.) | 3 |
| 20130131322 | ANTIBODY BEING CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING GROWTH-SUPPRESSING ACTIVITY ON CANCERS HAVING RAS GENE MUTATION - It has been found out that among antibodies showing reactivity with wild type TGF-α, antibodies less reactive with G79A-substituted TGF-α have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells. | 05-23-2013 |
| 20110071278 | ANTIBODIES THAT RECOGNIZE CUTTING EDGE WITHIN THE TGF- BETA ACTIVATION CONTROLLING REGION - It is an object of the present invention to provide antibodies capable of detecting an active TGF-β generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-β) generated as a result of generation of active form of human TGF-β1, human TGF-β2 and human TGF-β3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-β1, and corresponding regions of human TGF-β2 and human TGF-β3. | 03-24-2011 |
| 20130018176 | METHODS OF PRODUCING HYBRIDOMAS AND MONOCLONAL ANTIBODIES AND ANTIBODIES PRODUCED THEREBY - Disclosed are a method of producing a hybridoma, a method of making an antibody involving the hybridoma, and an antibody made by the method. | 01-17-2013 |
| 530388260 | Binds enzyme | 2 |
| 20110213129 | Diagnostics and treatments of periodontal disease - This invention relates to the PrtR-PrtK cell surface protein of | 09-01-2011 |
| 20130023654 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 01-24-2013 |
| 530388300 | Binds virus or component or product thereof (e.g., virus-associated antigen, etc.) | 2 |
| 20110301336 | ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF - Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies for medical use), which have been hardly produced by using the mammals such as the mouse and the rat, homogeneously in a single body, in large quantities and in a simple manner. The method can overcome a disadvantage of lot-to-lot variation which may occur in the production of polyclonal antibodies using other animals. | 12-08-2011 |
| 20090312527 | Novel monoclonal antibodies against HPV proteins - Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. Various monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, common epitope for various HPV proteins or HPV types are obtained. These obtained monoclonal antibodies are useful tools in early clinical detection of HPV infection and general detection of HPV related diseases, specific detection of invasive cervical cancer, detection of other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression. | 12-17-2009 |
| 530388400 | Binds bacterium or similar microorganism or component or product thereof (e.g., Stretococcus, Legionella, Mycoplasma, bacterium-associated antigen, exotoxin, etc.) | 8 |
| 20110201790 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201787 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201786 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201789 | ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201788 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20120208986 | USE OF MIXED MODE CHROMATOGRAPHY FOR THE CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS - Use of mixed mode chromatography for purification of an antibody from an antibody mixture, for example) a | 08-16-2012 |
| 20100016560 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-21-2010 |
| 20080262204 | RECOMBINANT ANTIBODIES FOR THE DETECTION AND NEUTRALIZATION OF ANTHRAX TOXIN - A composition and method for treating a host having or at risk of infection by | 10-23-2008 |
| 530388700 | Binds hematopoietic cell or component or product thereof (e.g., erythrocyte granulocyte, macrophage, monocyte, platelet, myelogenous leukemia cell, bone marrow stem cell, granulocytic cell-surface antigen, hemoglobin, thrombospondin, glycophorin, etc.) | 1 |
| 530388730 | Binds lymphocytic or lymphocytic-like cell or component or product thereof (e.g., B cell, B-lineage bone marrow cell, null cell, natural killer cell, B-lymphoblastoid cell, B-lineage acute lymphoblastic leukemia cell, B-lymphocytic cell-surface antigen, etc.) | 1 |
| 20100234578 | ANTI-CD40 MONOCLONAL ANTIBODY - An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. | 09-16-2010 |
| 530388800 | Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.) | 2 |
| 20120136140 | ANTI-CADHERIN ANTIBODY - It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 μg/mL is 30% or more. | 05-31-2012 |
| 530388850 | Binds antigen characterized by name or molecular weight (e.g., CEA, NCA, CC glycoprotein, melanoma gp 150 antigen, etc.) | 1 |
| 20080214791 | MONOCLONAL ANTIBODIES TO HUMAN HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN - The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes. | 09-04-2008 |
| 530388900 | Binds drug, hapten, hapten--carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.) | 8 |
| 20130030158 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12. | 01-31-2013 |
| 20080275221 | Busulfan Immunoassay - Novel conjugates of busulfan and novel busulfan immunogens derived from α-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids. | 11-06-2008 |
| 20080287658 | Docetaxel Immunoassay - Novel conjugates of docetaxel and novel docetaxel immunogens derived from the 7 and 10 positions of docetaxel and monoclonal antibodies generated by these docetaxel linked immunogens are useful in immunoassays for the quantification and monitoring of docetaxel in biological fluids. | 11-20-2008 |
| 20090036653 | Methods for the directed expansion of epitopes for use as antibody ligands - The instant invention comprises a process for selecting and manufacturing antibodies useful for therapeutic, prophylactic, diagnostic or research purposes using epitope peptide mixtures synthesized by the solid phase synthesis, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting antibodies are related to but distinct from antibodies that bind to the known epitope. | 02-05-2009 |
| 20120302740 | VINCRISTINE IMMUNOASSAY - Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids. | 11-29-2012 |
| 20080227959 | REAGENTS FOR DETECTING EFAVIRENZ - The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz. | 09-18-2008 |
| 20120071636 | RISPERIDONE IMMUNOASSAY - Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids. | 03-22-2012 |
| 20100204456 | 5-Fluoro-Uracil Immunoassay - Novel conjugates of 5-fluoro-uracil and novel 5-fluoro-uracil immunogens and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of 5-fluoro-uracil in biological fluids. | 08-12-2010 |
